Drug Maker Agrees To Pay $95M To Settle Federal Securities Law Claims
LOS ANGELES — A drug maker will pay $95 million to settle claims that it misrepresented certain safety concerns with two of its products in violation of federal securities laws, according...To view the full article, register now.
Already a subscriber? Click here to view full article